Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Biomimetic aggrecan reduces cartilage extracellular matrix from degradation and lowers catabolic activity in ex vivo and in vivo models.

Sharma S, Lee A, Choi K, Kim K, Youn I, Trippel SB, Panitch A.

Macromol Biosci. 2013 Sep;13(9):1228-37. doi: 10.1002/mabi.201300112.

PMID:
23836445
2.

Tenascin-C induces inflammatory mediators and matrix degradation in osteoarthritic cartilage.

Patel L, Sun W, Glasson SS, Morris EA, Flannery CR, Chockalingam PS.

BMC Musculoskelet Disord. 2011 Jul 15;12:164. doi: 10.1186/1471-2474-12-164.

3.

Biomimetic molecules lower catabolic expression and prevent chondroitin sulfate degradation in an osteoarthritic ex vivo model.

Sharma S, Vazquez-Portalatin N, Calve S, Panitch A.

ACS Biomater Sci Eng. 2016 Feb 8;2(2):241-250.

PMID:
26878059
4.

Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer II, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS.

J Clin Invest. 1997 Jul 1;100(1):93-106.

5.
6.

Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.

Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ.

Arthritis Rheum. 2003 Nov;48(11):3085-95.

7.

Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.

Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B.

Biochem J. 1999 Nov 15;344 Pt 1:61-8.

8.

Activation of cartilage matrix metalloproteinases by activated protein C.

Jackson MT, Smith MM, Smith SM, Jackson CJ, Xue M, Little CB.

Arthritis Rheum. 2009 Mar;60(3):780-91. doi: 10.1002/art.24303.

9.

Rho/ROCK and MEK/ERK activation by transforming growth factor-alpha induces articular cartilage degradation.

Appleton CT, Usmani SE, Mort JS, Beier F.

Lab Invest. 2010 Jan;90(1):20-30. doi: 10.1038/labinvest.2009.111.

10.

Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4.

Schelbergen RF, Blom AB, van den Bosch MH, Slöetjes A, Abdollahi-Roodsaz S, Schreurs BW, Mort JS, Vogl T, Roth J, van den Berg WB, van Lent PL.

Arthritis Rheum. 2012 May;64(5):1477-87. doi: 10.1002/art.33495.

11.

Hsp90 inhibition protects against biomechanically induced osteoarthritis in rats.

Siebelt M, Jahr H, Groen HC, Sandker M, Waarsing JH, Kops N, Müller C, van Eden W, de Jong M, Weinans H.

Arthritis Rheum. 2013 Aug;65(8):2102-12. doi: 10.1002/art.38000.

12.

MicroRNA-30a promotes extracellular matrix degradation in articular cartilage via downregulation of Sox9.

Chang T, Xie J, Li H, Li D, Liu P, Hu Y.

Cell Prolif. 2016 Apr;49(2):207-18. doi: 10.1111/cpr.12246.

PMID:
26969024
13.

Peptides of type II collagen can induce the cleavage of type II collagen and aggrecan in articular cartilage.

Yasuda T, Tchetina E, Ohsawa K, Roughley PJ, Wu W, Mousa A, Ionescu M, Pidoux I, Poole AR.

Matrix Biol. 2006 Sep;25(7):419-29.

PMID:
16919430
14.

Wnt/beta-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration.

Yuasa T, Otani T, Koike T, Iwamoto M, Enomoto-Iwamoto M.

Lab Invest. 2008 Mar;88(3):264-74. doi: 10.1038/labinvest.3700747.

16.

[A new mechanism of action of chondroitin sulfates ACS4-ACS6 in osteoarthritic cartilage].

Mathieu P.

Presse Med. 2002 Sep 14;31(29):1383-5. Review. French.

PMID:
12375394
17.

Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation.

Little CB, Hughes CE, Curtis CL, Janusz MJ, Bohne R, Wang-Weigand S, Taiwo YO, Mitchell PG, Otterness IG, Flannery CR, Caterson B.

Matrix Biol. 2002 Apr;21(3):271-88.

PMID:
12009333
18.

Identification of soluble 14-3-3∊ as a novel subchondral bone mediator involved in cartilage degradation in osteoarthritis.

Priam S, Bougault C, Houard X, Gosset M, Salvat C, Berenbaum F, Jacques C.

Arthritis Rheum. 2013 Jul;65(7):1831-42. doi: 10.1002/art.37951.

20.

Intra-articular injection of tumor necrosis factor-alpha in the rat: an acute and reversible in vivo model of cartilage proteoglycan degradation.

Malfait AM, Tortorella M, Thompson J, Hills R, Meyer DM, Jaffee BD, Chinn K, Ghoreishi-Haack N, Markosyan S, Arner EC.

Osteoarthritis Cartilage. 2009 May;17(5):627-35. doi: 10.1016/j.joca.2008.10.005.

Items per page

Supplemental Content

Support Center